Nonalcoholic fatty liver disease increases the risk of cardiovascular disease through mechanisms including systemic inflammation, endothelial dysfunction, and insulin resistance.
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both manifestations of end-organ damage of the metabolic syndrome. Through multiple pathophysiological mechanisms, CVD and NAFLD are associated with each other. Systemic inflammation, endothelial dysfunction, hepatic insulin resistance, oxidative stress, and altered lipid metabolism are some of the mechanisms by which NAFLD increases the risk of CVD. Patients with NAFLD develop increased atherosclerosis, cardiomyopathy, and arrhythmia, which clinically result in cardiovascular morbidity and mortality. Defining the mechanisms linking these 2 diseases offers the opportunity to further develop targeted therapies. The aim of this comprehensive review is to examine the association between CVD and NAFLD and discuss the overlapping management approaches.
Stahl et al. (Mon,) conducted a review in Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Nonalcoholic fatty liver disease increases the risk of cardiovascular disease through mechanisms including systemic inflammation, endothelial dysfunction, and insulin resistance.